Atezolizumab

Generic Name
Atezolizumab
Brand Names
Tecentriq
Drug Type
Biotech
Chemical Formula
-
CAS Number
1380723-44-3
Unique Ingredient Identifier
52CMI0WC3Y
Background

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication

Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions
Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
Associated Therapies
-

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

First Posted Date
2021-10-27
Last Posted Date
2024-08-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT05096715
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

First Posted Date
2021-10-26
Last Posted Date
2022-10-17
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
2
Registration Number
NCT05093608
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

First Posted Date
2021-10-25
Last Posted Date
2024-10-29
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
690
Registration Number
NCT05091567
Locations
🇺🇸

Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States

🇺🇸

Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States

🇺🇸

SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States

and more 103 locations

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

First Posted Date
2021-09-28
Last Posted Date
2024-02-20
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
7
Registration Number
NCT05060003
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Radiotherapy in Combination with Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

First Posted Date
2021-09-22
Last Posted Date
2024-10-22
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
11
Registration Number
NCT05053737
Locations
🇺🇸

Colorado Research Center, Aurora, Colorado, United States

🇺🇸

Memorial Hospital North, Colorado Springs, Colorado, United States

🇺🇸

Memorial Health Central, Colorado Springs, Colorado, United States

and more 1 locations

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2021-09-17
Last Posted Date
2024-12-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
60
Registration Number
NCT05047250
Locations
🇨🇳

The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou City, China

🇨🇳

Linyishi Cancer Hospital, Linyi City, China

🇨🇳

Jiangsu Cancer Hospital, Nanjing City, China

and more 26 locations

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

First Posted Date
2021-09-09
Last Posted Date
2022-10-03
Lead Sponsor
University Hospital Southampton NHS Foundation Trust
Target Recruit Count
36
Registration Number
NCT05038657
Locations
🇬🇧

University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath